4Gianni L, Pienkowski T, Im Y H, et al. Efficacy and safety ofneoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or early HER2-positive breast cancer (NeoSphere) : arandomised multicentre open-label phase 2 trial [ J ]. Lancet Oncol, 2012,13 ( 1 ) :25-32.
5Gianni L, Eiermann W J, Semiglazov V, et al. Neoad ju-vant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone in patients with HER2-positive locally advanced breast canc- er(the NOAH trial) :A randomised controlled superiority trial with aparallel HER2-uegative cohort [ J ]. Lancet, 2010,15(6) :375-377.
6Lari S A, Kuerer H M. Biological markers in DCIS and risk of breast recurrence: a systematic review[ J]. Cancer 2011,2( 1 ) :232-261.
7Albonico G, Querzoli P, Ferretti S, et al. Biological pro- file of in situ breast cancer investigated by immunohisto- chemical technique [ J]. Cancer Detect Prey, 1998,22 (4) :313-318.
8Elledge R M, Allred D C. The p53 tumor suppressor gene in breast cancer[ J]. Breast Cancer Res Treatment , 1994,32( 1 ) :39-47.
10Michishita S, Kim SJ, Shimazu K, et al. Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic reso- nance imaging in breast cancer patients[J]. Breast, 2015,24 ( 2 ) : 159- 165.
